137 related articles for article (PubMed ID: 38564986)
41. Enasidenib.
Krämer A; Bochtler T
Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
[TBL] [Abstract][Full Text] [Related]
42. [Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
Shang Z; Wang D; Xiao M; Wang J; Li TJ; Zhao YC; Li CR; Zhou JF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):607-12. PubMed ID: 23815907
[TBL] [Abstract][Full Text] [Related]
43. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
[TBL] [Abstract][Full Text] [Related]
44.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract][Full Text] [Related]
45. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
46. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
Wang L; Song J; Xiao X; Li D; Liu T; He X
J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
[TBL] [Abstract][Full Text] [Related]
47. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
48. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
[TBL] [Abstract][Full Text] [Related]
49. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
50. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
[TBL] [Abstract][Full Text] [Related]
51. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
52. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
[TBL] [Abstract][Full Text] [Related]
53. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
54. Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.
Nomdedéu J; Hoyos M; Carricondo M; Esteve J; Bussaglia E; Estivill C; Ribera JM; Duarte R; Salamero O; Gallardo D; Pedro C; Aventin A; Brunet S; Sierra J
Leuk Res; 2012 Aug; 36(8):990-7. PubMed ID: 22520341
[TBL] [Abstract][Full Text] [Related]
55. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
56. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
57. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
Luo LQ; Peng ZY; Liu X; Yu WZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
[TBL] [Abstract][Full Text] [Related]
58. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
[TBL] [Abstract][Full Text] [Related]
59. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
Chou WC; Lei WC; Ko BS; Hou HA; Chen CY; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Leukemia; 2011 Feb; 25(2):246-53. PubMed ID: 21079611
[TBL] [Abstract][Full Text] [Related]
60. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
